Nanjing Vcare Ranked Top 8 in "China's Top 20 Pharmaceutical CRO Enterprises" for Four Consecutive Years

2025-06-20

　　On June 20th, the "2025 PDI Pharmaceutical R&D and Innovation Conference & China's Top 100 Pharmaceutical R&D Companies Awards Ceremony" unveiled the "2025 China Pharmaceutical R&D Competitiveness Ranking Series." Nanjing Vcare Pharmatech Co., Ltd. (Nanjing Vcare) was once again honored in the "China's Top 20 Pharmaceutical CRO Enterprises" list, securing the 8th position and marking its fourth consecutive year in the TOP 10. Additionally, its subsidiary Hubei Tianshu Pharmaceutical Co., Ltd. (Tianshu Pharmaceutical) made its debut on the "China's Top 20 Pharmaceutical CDMO Enterprises" list.

　　These dual accolades in the R&D competitiveness rankings demonstrate the high recognition from industry leaders and peers for Nanjing Vcare's innovation capabilities, technical expertise, and growth potential.

　　With a global vision, Nanjing Vcare remains committed to innovation and resource integration, focusing on end-to-end R&D and production services across the entire chemical drug value chain and lifecycle. The company continues to strengthen its CRO/CDMO service capabilities while exploring sustainable development pathways. By advancing core technologies in synthetic biology and green chemistry, Nanjing Vcare has established platforms such as photochemistry, continuous flow engineering, and biocatalytic engineering.

　　Moving forward, we aim to collaborate with global pharmaceutical companies and drug R&D institutions to support medical innovation. Our comprehensive services span from CDMO production and supply of pharmaceutical intermediates to APIs, as well as integrated, differentiated, and customized solutions covering pharmaceutical CMC, clinical CRO studies, and regulatory affairs—empowering our partners' success at every stage.

Next

Nanjing Vcare Selected for Nanjing Enterprise Technology Center Incubation Program